Unless you’ve been living under a rock for the last few years, you’ve heard about GLP-1 medications. Ozempic. Wegovy. Mounjaro. Zepbound, or the generics Semaglutide and tirzepatide. They’ve completely changed the conversation around weight loss—and, frankly, they’ve changed medicine.
But what I find most interesting about GLP-1 medications isn’t simply their ability to help people lose weight.
We’re discovering that the GLP-1 system is involved in much more than appetite. It intersects with blood sugar regulation, insulin sensitivity, cardiovascular health, inflammation, the brain, reward pathways, sleep, and potentially even healthy aging.
And I think we’re still at the beginning of understanding what these medications can do.
First, What Exactly Is GLP-1?
GLP-1 stands for glucagon-like peptide-1.
It’s actually a hormone your body already makes, primarily in the gut after you eat. GLP-1 communicates with multiple systems throughout the body and helps regulate things like:
- Insulin secretion
- Glucagon production
- Blood sugar
- Gastric emptying
- Appetite
- Aatiety
- Communication between the gut and brain
Medications such as semaglutide mimic GLP-1 activity but last much longer than our naturally produced GLP-1.
Tirzepatide goes a step further and activates both GLP-1 and GIP receptors, another pathway involved in metabolic regulation.
That’s why I don’t really think of these medications simply as “weight-loss drugs.” They are metabolic signaling medications. And that distinction matters.
The Weight Loss Is Important—but So Is What Happens Underneath It
For many people with insulin resistance, losing weight isn’t as simple as eating less and exercising more.
Insulin resistance changes hunger signals, energy storage, blood sugar regulation and metabolic flexibility. Add menopause, poor sleep, chronic stress, inflammation, genetics or certain medications, and losing weight can become incredibly difficult.
GLP-1 medications can help change that physiology.
Patients frequently tell me something fascinating happens when they start one: The food noise gets quieter.
They’re not constantly thinking about what they’re going to eat next. They’re satisfied after a reasonable meal. Cravings decrease. For someone who has spent decades fighting hunger with willpower, that can be life-changing. But the metabolic improvements extend beyond appetite.
GLP-1s and Cardiovascular Health
This is one of the areas where the evidence has become particularly compelling. In the large SELECT cardiovascular-outcomes trial, more than 17,000 adults who had overweight or obesity and established cardiovascular disease but did not have diabetes were followed for approximately 40 months.
Those receiving semaglutide had a 20% lower relative risk of the study’s combined cardiovascular endpoint of cardiovascular death, nonfatal heart attack or nonfatal stroke compared with placebo.
That matters because it tells us these medications aren’t simply changing someone’s appearance or a number on the scale. They can affect meaningful health outcomes. For me, that’s where the longevity conversation becomes much more interesting.
What About Inflammation?
This is an emerging area that I’m watching closely. Obesity, insulin resistance and visceral fat are associated with chronic low-grade inflammation. We sometimes refer to this age-associated inflammatory state as “inflammaging.”
GLP-1 medications appear to influence inflammatory pathways, although researchers are still teasing apart how much comes directly from GLP-1 signaling versus the downstream effects of weight loss and improved metabolic health. Either way, improving visceral adiposity, insulin resistance and metabolic dysfunction can substantially change the inflammatory environment of the body. And that has implications far beyond weight.
The Brain May Be Part of the Story Too
GLP-1 receptors aren’t limited to the gut and pancreas. They’re also found within the central nervous system. That’s one reason researchers are so interested in GLP-1 medications for neurological disease.
There has been considerable research into potential effects on neuroinflammation, oxidative stress and neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease. But this is where we need to be careful about the hype. Promising biology doesn’t always translate into a successful treatment.
For example, semaglutide showed interesting effects on several Alzheimer’s-related biomarkers, but large Phase 3 trials in early Alzheimer’s disease did not demonstrate the hoped-for improvement in cognitive outcomes.
So, I wouldn’t tell someone to take a GLP-1 to prevent Alzheimer’s. What I would say is that the relationship between metabolic health and brain health is becoming increasingly difficult to ignore.
And that is something we should all be paying attention to.
The “Food Noise” Effect May Extend Beyond Food
Here’s another fascinating area. Some patients taking GLP-1 medications report decreased desire not only for food, but also for alcohol and other rewarding behaviors.
Researchers are now studying GLP-1 signaling within the brain’s reward pathways and its possible role in substance-use disorders. This is still an emerging field—not an established indication for these medications—but it’s another reminder that GLP-1 is doing much more in the body than controlling blood sugar.
GLP-1s and Sleep Apnea
This is another area where the evidence has become surprisingly strong. In clinical trials of people with obesity and moderate-to-severe obstructive sleep apnea, tirzepatide significantly reduced the severity of sleep apnea while also improving body weight, inflammatory markers, blood pressure and patient-reported sleep outcomes.
Again, some of this undoubtedly relates to weight loss. But think about the downstream effects.
Better sleep can improve:
insulin sensitivity → cortisol regulation → appetite → blood pressure → inflammation → cognition → energy
This is why functional medicine often looks at systems rather than isolated diagnoses. Every system talks to every other system.
So, Are GLP-1s Longevity Drugs?
I wouldn’t go that far. We don’t currently have evidence showing that taking a GLP-1 simply makes otherwise healthy humans live longer. But we do have increasingly good evidence that these medications can improve several conditions strongly associated with healthspan and cardiovascular risk.
And that’s an important distinction.
But There Is Another Side to This Conversation
I am very enthusiastic about GLP-1 medications.
I’m also cautious about how they’re being used.
I believe that more medication is not always better.
And rapid weight loss can come with consequences:
- Loss of muscle
- Inadequate protein intake
- Nutrient deficiencies
- Constipation
- Nausea
- Gallbladder problems
- Hair shedding
- Fatigue
- Excessive loss of lean body mass
And muscle loss is the exact opposite of what we want in longevity medicine.
This becomes especially important for women in perimenopause and menopause, who are already navigating changes in estrogen, insulin sensitivity, visceral fat distribution, bone density and muscle mass. If we’re helping a 52-year-old woman lose 30 pounds but a significant portion of that loss is muscle, I don’t consider that an optimal outcome.
The goal isn’t simply to make someone smaller. The goal is to make them metabolically healthier and stronger.
This Is Why I Don’t Believe in One-Size-Fits-All GLP-1 Treatment
Not everyone needs the maximum tolerated dose.
And not everyone needs the same strategy.
In our practice, we’re interested in finding the lowest effective dose that accomplishes the patient’s metabolic goals while minimizing side effects and preserving nutrition and muscle.
There is also growing interest in what people commonly call microdosing” GLP-1 medications – using doses below standard therapeutic dosing.
I think this is an interesting area, particularly for certain metabolically sensitive patients, but it’s important to be transparent: microdosing is not an FDA-approved GLP-1 treatment strategy, and we don’t yet have robust clinical trials establishing its long-term benefits or ideal dosing.
That’s an area where clinical enthusiasm has moved faster than the research. I think patients deserve to know the difference.
What I Monitor in My GLP-1 Patients
Weight is only one piece of the picture.
Depending on the patient, I’m also thinking about:
Insulin resistance.
Fasting glucose and A1c don’t always tell th
e whole story. Fasting insulin and sometimes continuous glucose monitoring can provide additional information about metabolic health.
Body composition.
Are we losing visceral fat while preserving muscle?
Protein intake.
If appetite drops dramatically, protein often drops with it.
Muscle.
Resistance training becomes incredibly important.
Nutrients.
Someone eating substantially less food may also be consuming fewer vitamins, minerals and essential nutrients.
GI function.
GLP-1 medications slow gastric emptying and can affect motility, constipation and other GI symptoms.
Especially in perimenopausal and menopausal women, metabolic health doesn’t exist independently from estrogen, progesterone, testosterone, thyroid function and stress physiology.
And perhaps most importantly: How does the patient actually feel?
Are they experiencing more energy? Better sleep? Less inflammation? Stronger? Clearer thinking? Or are they exhausted, nauseated and barely eating?
Those are very different outcomes and require different management approaches.
Where I Think GLP-1 Medicine Is Going
I suspect the next chapter of GLP-1 medicine will look very different from the first.
The first chapter was: Diabetes. Then came: Weight loss.
Now researchers are asking much bigger questions involving cardiovascular disease, sleep apnea, kidney disease, liver disease, inflammation, brain health, reward pathways and metabolic aging.
Some of these applications will probably hold up beautifully in clinical trials. Others won’t.
That’s how medicine evolves. And that’s also why I think it’s important to remain both curious and skeptical. We can be excited about emerging therapies without pretending we already know everything about them.
The Bottom Line
GLP-1 medications have fundamentally changed how we think about obesity and metabolic disease. They’ve also helped move us away from the outdated idea that weight is simply a matter of willpower.
But I think their bigger contribution may ultimately be helping us understand something much more important: Metabolism affects nearly every system in the body.
The gut talks to the brain. Muscle talks to metabolism. Hormones influence insulin sensitivity. Sleep influences appetite. Visceral fat influences inflammation. And metabolic health influences how we age.
That’s why I think the most interesting question about GLP-1s is no longer:
“How much weight can I lose?”
It’s: “How can we use these tools to become healthier—not simply smaller?”
And that’s the conversation I think we should be having.
Interested in a More Personalized Approach to Metabolic Health?
At Boulder Holistic Functional Medicine in Boulder, Colorado, we take an individualized approach to metabolic health and GLP-1 therapy. That means looking beyond the scale at insulin resistance, hormones, body composition, nutrition, muscle preservation, gut health, sleep and the other factors that influence how you feel and age.
If you’re curious whether GLP-1 therapy—or another metabolic strategy—might make sense for you, schedule a consultation with our team.
This article is for educational purposes only and is not intended as individual medical advice. GLP-1 medications are prescription medications with potential risks, contraindications and side effects and should be used under appropriate medical supervision.
